<i>Clostridium sporogenes</i>
 delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity

Zhang, Y.-L.; Lü, Rui; Chang, Zhishang; Zhang, W.-Q.; Wang, Q.-B.; Ding, Suchun; Zhao, Wenwen

doi:10.1111/lam.12322

Cited by 20 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112,113 Once C. novyi-NT spores reach cancer cells, they induce expression of specific antibodies against hypoxia inducing factor-1 (HIF-1) as well as different cytokines such as TNF-α, IL-2 and IL-12 to inhibit the growth of the cancer cells and angiogenesis. 114…”

Section: Dovepressmentioning

confidence: 99%

Bacteria-Based Nanoprobes for Cancer Therapy

Lu,

Mei,

Ying

et al. 2024

IJN

View full text Add to dashboard Cite

Surgical removal together with chemotherapy and radiotherapy has used to be the pillars of cancer treatment. Although these traditional methods are still considered as the first-line or standard treatments, non-operative situation, systemic toxicity or resistance severely weakened the therapeutic effect. More recently, synthetic biological nanocarriers elicited substantial interest and exhibited promising potential for combating cancer. In particular, bacteria and their derivatives are omnipotent to realize intrinsic tumor targeting and inhibit tumor growth with anti-cancer agents secreted and immune response. They are frequently employed in synergistic bacteria-mediated anticancer treatments to strengthen the effectiveness of anti-cancer treatment. In this review, we elaborate on the development, mechanism and advantage of bacterial therapy against cancer and then systematically introduce the bacteria-based nanoprobes against cancer and the recent achievements in synergistic treatment strategies and clinical trials. We also discuss the advantages as well as the limitations of these bacteria-based nanoprobes, especially the questions that hinder their application in human, exhibiting this novel anti-cancer endeavor comprehensively.

show abstract

Section: Dovepressmentioning

confidence: 99%

Bacteria-Based Nanoprobes for Cancer Therapy

Lu,

Mei,

Ying

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…The other microbial vector is the bacterium, and other reviews are available that discuss this platform in detail 270‐275 . Commonly used strains include Clostridium , Salmonella , and Listeria .…”

Section: Cancer Vaccine Platformsmentioning

confidence: 99%

“…The other microbial vector is the bacterium, and other reviews are available that discuss this platform in detail. [270][271][272][273][274][275] Commonly used strains include Clostridium, Salmonella, and Listeria. A modified Salmonella vaccine was tested for dose, safety, tolerability, and immune response in patients with refractory solid tumors (NCT00006254, NCT00004216).…”

Section: Microbial Vector Vaccines-oncolytic and Bacterialmentioning

confidence: 99%

Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside

Roy

Sethi

Taylor

et al. 2020

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Clinical approval of the immune checkpoint blockade (ICB) agents for multiple cancer types has reinvigorated the long-standing work on cancer vaccines. In the pre-ICB era, clinical efforts focused on the Ag, the adjuvants, the formulation, and the mode of delivery. These translational efforts on therapeutic vaccines range from cell-based (e.g., dendritic cells vaccine Sipuleucel-T) to DNA/RNA-based platforms with various formulations (liposome), vectors (Listeria monocytogenes), or modes of delivery (intratumoral, gene gun, etc.). Despite promising preclinical results, cancer vaccine trials without ICB have historically shown little clinical activity. With the anticipation and expansion of combinatorial immunotherapeutic trials with ICB, the cancer vaccine field has entered the personalized medicine arena with recent advances in immunogenic neoantigenbased vaccines. In this article, we review the literature to organize the different cancer vaccines in the clinical space, and we will discuss their advantages, limits, and recent progress to overcome their challenges. Furthermore, we will also discuss recent preclinical advances and clinical strategies to combine vaccines with checkpoint blockade to improve therapeutic outcome and present a translational perspective on future directions.

show abstract

“…Clostridium species can be engineered to deliver molecules to tumors that decrease their aggressiveness without producing negative effects on the body. Of these, Clostridium novyi -NT AC and Clostridium sporogenes NCIMB 10696 are modified to produce anti-HIF1A antibodies, inhibiting the angiogenic signaling pathway at an early stage ( 34 ), and Clostridium sporogenes ATCC 3584 is modified to deliver IL12, selectively amplifying IFN gamma secretion and affecting tumor growth ( 35 ).…”

Section: Introductionmentioning

confidence: 99%

Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies

Constantin,

Chifiriuc,

Mihaescu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Cancer is a very aggressive disease and one of mankind’s most important health problems, causing numerous deaths each year. Its etiology is complex, including genetic, gender-related, infectious diseases, dysbiosis, immunological imbalances, lifestyle, including dietary factors, pollution etc. Cancer patients also become immunosuppressed, frequently as side effects of chemotherapy and radiotherapy, and prone to infections, which further promote the proliferation of tumor cells. In recent decades, the role and importance of the microbiota in cancer has become a hot spot in human biology research, bringing together oncology and human microbiology. In addition to their roles in the etiology of different cancers, microorganisms interact with tumor cells and may be involved in modulating their response to treatment and in the toxicity of anti-tumor therapies. In this review, we present an update on the roles of microbiota in cancer with a focus on interference with anticancer treatments and anticancer potential.

show abstract

Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity

Cited by 20 publications

References 23 publications

Bacteria-Based Nanoprobes for Cancer Therapy

Bacteria-Based Nanoprobes for Cancer Therapy

Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside

Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies

Contact Info

Product

Resources

About